FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2342440786> ?p ?o ?g. }

• W2342440786 endingPage "2036" @default.
• W2342440786 startingPage "2028" @default.
• W2342440786 abstract "Purpose To compare patients with high-risk stage III to IV Hodgkin lymphoma (HL) in the phase III European Organisation for Research and Treatment of Cancer 20012 Intergroup trial (Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin’s Lymphoma) who were randomly assigned to either doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) or to bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP). Patients and Methods Patients with clinical stage III or IV HL, International Prognostic Score of 3 or higher, and age 60 years or younger received ABVD for eight cycles (ABVD 8 ) or escalated-dose BEACOPP (BEACOPP escalated ) for four cycles followed by baseline BEACOPP (BEACOPP baseline ) for four cycles (BEACOPP 4+4 ) without radiotherapy. Primary end points were event-free survival (EFS), treatment discontinuation, no complete response (CR) or unconfirmed complete response (CRu) after eight cycles, progression, relapse, or death. Secondary end points were CR rate, overall survival (OS), quality of life, secondary malignancies, and disease-free survival in CR/CRu patients. Results Between 2002 and 2010, 549 patients were randomly assigned to ABVD 8 (n = 275) or BEACOPP 4+4 (n = 274). Other characteristics included median age, 35 years; male, 75%; stage IV, 74%; “B” symptoms, 81%; and International Prognostic Score ≥ 4, 59%. WHO performance status was 0 (34%), 1 (48%), or 2 (17%). Median follow-up was 3.6 years. CR/CRu was 82.5% in both arms. At 4 years, EFS was 63.7% for ABVD 8 versus 69.3% for BEACOPP 4+4 (hazard ratio [HR], 0.86; 95% CI, 0.64 to 1.15; P = .312); disease-free survival was 85.8% versus 91.0% (HR, 0.59; 95% CI, 0.33 to 1.06; P = .076), and OS was 86.7% versus 90.3% (HR, 0.71; 95% CI, 0.42 to 1.21; P = .208). Death as a result of toxicity occurred in six and five patients, early discontinuation (before cycle 5) in 12 and 26 patients, treatment crossovers in five and 10 patients, and secondary malignancies in eight and 10 patients in the ABVD 8 and BEACOPP 4+4 arms, respectively. Conclusion ABVD 8 and BEACOPP 4+4 resulted in similar EFS and OS in patients with high-risk advanced-stage HL. Because BEACOPP 4+4 did not demonstrate a favorable effectiveness or toxicity ratio compared with ABVD 8 , treatment burden, immediate and late toxicities, and associated costs must be considered before selecting one of these regimens on which to build future treatment strategies." @default.
• W2342440786 created "2016-06-24" @default.
• W2342440786 creator A5001557317 @default.
• W2342440786 creator A5001602966 @default.
• W2342440786 creator A5003105021 @default.
• W2342440786 creator A5006682547 @default.
• W2342440786 creator A5013366285 @default.
• W2342440786 creator A5035799376 @default.
• W2342440786 creator A5037155506 @default.
• W2342440786 creator A5038609604 @default.
• W2342440786 creator A5044651904 @default.
• W2342440786 creator A5050884991 @default.
• W2342440786 creator A5052167942 @default.
• W2342440786 creator A5054677442 @default.
• W2342440786 creator A5056514957 @default.
• W2342440786 creator A5062305482 @default.
• W2342440786 creator A5063170420 @default.
• W2342440786 creator A5069105295 @default.
• W2342440786 creator A5070096062 @default.
• W2342440786 creator A5070508738 @default.
• W2342440786 creator A5075950291 @default.
• W2342440786 creator A5085810268 @default.
• W2342440786 date "2016-06-10" @default.
• W2342440786 modified "2023-10-03" @default.
• W2342440786 title "Eight Cycles of ABVD Versus Four Cycles of BEACOPP_escalatedPlus Four Cycles of BEACOPP_baselinein Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial" @default.
• W2342440786 cites W126593993 @default.
• W2342440786 cites W1912693401 @default.
• W2342440786 cites W1973535185 @default.
• W2342440786 cites W1976281058 @default.
• W2342440786 cites W1978054534 @default.
• W2342440786 cites W2001261680 @default.
• W2342440786 cites W2019618564 @default.
• W2342440786 cites W2024136031 @default.
• W2342440786 cites W2052924000 @default.
• W2342440786 cites W2076334524 @default.
• W2342440786 cites W2078016415 @default.
• W2342440786 cites W2083616014 @default.
• W2342440786 cites W2083951917 @default.
• W2342440786 cites W2090824711 @default.
• W2342440786 cites W2092192760 @default.
• W2342440786 cites W2101873015 @default.
• W2342440786 cites W2104221398 @default.
• W2342440786 cites W2106187927 @default.
• W2342440786 cites W2107089248 @default.
• W2342440786 cites W2109686908 @default.
• W2342440786 cites W2118169390 @default.
• W2342440786 cites W2131358677 @default.
• W2342440786 cites W2133260927 @default.
• W2342440786 cites W2136962826 @default.
• W2342440786 cites W2139132694 @default.
• W2342440786 cites W2142226790 @default.
• W2342440786 cites W2142757611 @default.
• W2342440786 cites W2142880562 @default.
• W2342440786 cites W2148916166 @default.
• W2342440786 cites W2150274226 @default.
• W2342440786 cites W2156613346 @default.
• W2342440786 cites W2157717016 @default.
• W2342440786 cites W2158830277 @default.
• W2342440786 cites W2164900174 @default.
• W2342440786 cites W2165308914 @default.
• W2342440786 cites W2229559212 @default.
• W2342440786 cites W2229695843 @default.
• W2342440786 cites W2328676772 @default.
• W2342440786 cites W2586127382 @default.
• W2342440786 cites W4293241248 @default.
• W2342440786 cites W1988755905 @default.
• W2342440786 doi "https://doi.org/10.1200/jco.2015.64.5648" @default.
• W2342440786 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27114593" @default.
• W2342440786 hasPublicationYear "2016" @default.
• W2342440786 type Work @default.
• W2342440786 sameAs 2342440786 @default.
• W2342440786 citedByCount "98" @default.
• W2342440786 countsByYear W23424407862016 @default.
• W2342440786 countsByYear W23424407862017 @default.
• W2342440786 countsByYear W23424407862018 @default.
• W2342440786 countsByYear W23424407862019 @default.
• W2342440786 countsByYear W23424407862020 @default.
• W2342440786 countsByYear W23424407862021 @default.
• W2342440786 countsByYear W23424407862022 @default.
• W2342440786 countsByYear W23424407862023 @default.
• W2342440786 crossrefType "journal-article" @default.
• W2342440786 hasAuthorship W2342440786A5001557317 @default.
• W2342440786 hasAuthorship W2342440786A5001602966 @default.
• W2342440786 hasAuthorship W2342440786A5003105021 @default.
• W2342440786 hasAuthorship W2342440786A5006682547 @default.
• W2342440786 hasAuthorship W2342440786A5013366285 @default.
• W2342440786 hasAuthorship W2342440786A5035799376 @default.
• W2342440786 hasAuthorship W2342440786A5037155506 @default.
• W2342440786 hasAuthorship W2342440786A5038609604 @default.
• W2342440786 hasAuthorship W2342440786A5044651904 @default.
• W2342440786 hasAuthorship W2342440786A5050884991 @default.
• W2342440786 hasAuthorship W2342440786A5052167942 @default.
• W2342440786 hasAuthorship W2342440786A5054677442 @default.
• W2342440786 hasAuthorship W2342440786A5056514957 @default.
• W2342440786 hasAuthorship W2342440786A5062305482 @default.
• W2342440786 hasAuthorship W2342440786A5063170420 @default.
• W2342440786 hasAuthorship W2342440786A5069105295 @default.
• W2342440786 hasAuthorship W2342440786A5070096062 @default.

• next